Yes, Abrupt Beta-Blocker Cessation Can Cause Tachycardia
Sudden discontinuation of beta-blockers causes a withdrawal syndrome characterized by tachycardia, typically occurring 36-72 hours after cessation, due to increased beta-receptor sensitivity and sympathetic overactivity. 1
Mechanism and Clinical Presentation
When beta-blockers are stopped abruptly, patients experience a rebound phenomenon driven by:
- Upregulated beta-receptors that developed during chronic therapy
- Increased receptor sensitivity to endogenous catecholamines
- Sympathetic hyperresponsiveness without increased circulating catecholamine levels 2
The withdrawal syndrome manifests with:
- Tachycardia (heart rate "overshoot" above pre-treatment baseline) 3
- Palpitations, tremor, sweating
- Headache and general malaise
- Nervousness and agitation 1
Serious Cardiovascular Consequences
Beyond tachycardia, abrupt cessation carries significant morbidity and mortality risks:
In patients with coronary artery disease, beta-blocker withdrawal is associated with:
- 4-fold increase in coronary heart disease events (RR 4.5,95% CI 1.1 to 18.5) 4
- 2.7-fold increased risk of MI within 30 days (RR 2.70,95% CI 1.06 to 6.89) 4
- Unstable angina and myocardial infarction from increased myocardial oxygen demand 3
In perioperative settings, discontinuation is particularly dangerous:
- 50% mortality in patients who had beta-blockers stopped postoperatively versus 1.5% in those continued (OR 65.0) 4
- 2.7-fold increased 1-year mortality compared to non-users (HR 2.7,95% CI 1.2 to 5.9) 4
Prevention Strategy
The best treatment is prevention through gradual tapering over 7-10 days 5. The ACC/AHA guidelines provide a Class I recommendation for continuation of beta-blocker therapy in the perioperative period, explicitly stating that "perioperative beta-blocker withdrawal should be avoided unless necessary" 4.
If Withdrawal Syndrome Develops:
- Re-administer the previously discontinued beta-blocker as first-line treatment 5
- For hypertensive crisis from combined withdrawal (e.g., clonidine + beta-blocker), labetalol with both alpha- and beta-blocking properties is particularly effective 6
Clinical Caveats
Withdrawal symptoms are reproducible in susceptible patients 2. Risk factors for severe withdrawal include:
- High doses of beta-blockers
- Ischemic heart disease
- Severe hypertension
- Combination antihypertensive therapy 5
Beta-blockers with partial agonist activity (intrinsic sympathomimetic activity) may produce less severe withdrawal reactions 3.
The syndrome appears rare in patients on standard doses, but the consequences when it occurs—particularly tachycardia leading to increased myocardial oxygen demand in vulnerable patients—can be catastrophic 1, 3.